HEMOGENYX PHARMACEUTICALS PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 25, 2021

National Storage Mechanism | Additional information

RNS Number : 2125D

Hemogenyx Pharmaceuticals PLC

25 June 2021

25 June 2021

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

AGM Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To adopt the 2020 Annual Report and Accounts​	126,557,317	99.87%	168,193	0.13%	126,725,510	12.93%	289,150
2. To approve the Directors' Remuneration Policy​	125,619,330	99.07%	1,177,033	0.93%	126,796,363	12.94%	218,297
3. To approve the Directors' Remuneration Report​	125,638,477	99.07%	1,177,033	0.93%	126,815,510	12.94%	199,150
4. To reappoint the Company's auditor​	126,528,170	99.87%	168,193	0.13%	126,696,363	12.93%	318,297
5. To authorise the Audit Committee to determine the auditor's remuneration​	126,356,107	99.72%	350,256	0.28%	126,706,363	12.93%	308,297
6. To re-elect Sir Marc Feldmann as a director of the Company	125,895,121	99.28%	911,242	0.72%	126,806,363	12.94%	208,297
7. To authorise the Directors to allot equity securities​	125,663,209	99.11%	1,133,154	0.89%	126,796,363	12.94%	218,297
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
8. To disapply pre-emption provisions​	123,047,368	97.04%	3,748,995	2.96%	126,796,363	12.94%	218,297
9. To adopt new Articles of Association​	125,663,209	99.27%	923,154	0.73%	126,586,363	12.92%	428,297
10. To adopt new Articles of Association​	126,014,268	99.36%	811,242	0.64%	126,825,510	12.94%	189,150

(1)        The Company's issued share capital ("ISC") on 23 June 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 979,749,321 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKPBNQBKDDAB